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Vif is required for HIV-1 replication in natural target cells by counteracting host restriction 
factors, APOBEC3 (A3) proteins. We recently demonstrated that Vif expression level can 
be changed by naturally occurring single-nucleotide variations within SA1D2prox of the 
HIV-1 genome. We also found that levels for vif/vpr mRNAs are inversely correlated. While 
amino acid sequence per se is critical for functionality, Vif expression level modulated by 
signal sequences in its coding region is likely to be important as well. There are two splicing 
sites in the region involved in vpr expression. To reveal possible fluctuations of Vif-expression 
level, we examined SA1D2prox and vif gene by chimeric approaches using HIV-1 subtypes 
B and C with distinct anti-A3 activity. In this report, recombinant clones in subtype B 
backbone carrying chimeric sequences with respect to SA1D2prox/vif and those within 
the vif-coding region were generated. Of these, clones containing vif-coding sequence 
of subtype C, especially its 3′ region, expressed vif/Vif at a decreased level but did at an 
increased level for vpr/Vpr. Clones with reduced vif/Vif level grew similarly or slightly better 
than a parental clone in weakly A3G-positive cells but more poorly in highly A3G-expressing 
cells. Three clones with this property were also tested for their A3-degrading activity. One 
of the clones appeared to have some defect in addition to the poor ability to express 
vif/Vif. Taken all together, our results show that natural variations in the SA1D2prox and 
vif-coding region can change the Vif-expression level and affect the HIV-1 replication potential.
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INTRODUCTION
HIV-1 Vif antagonize host intrinsic restriction factors, A3 proteins (A3s) (Malim and Emerman, 
2008; Harris et  al., 2012; Malim and Bieniasz, 2012; Aydin et  al., 2014; Desimmie et  al., 2014; 
Feng et  al., 2014; Okada and Iwatani, 2016). A3 family of cytidine deaminases consists of seven 
members (A, B, C, D, F, G, and H). Of these, A3D, A3F, A3G, and certain haplotypes of A3H 
potently inhibit HIV-1 replication, A3G in particular, by deaminase-dependent and -independent 
mechanisms. HIV-1 Vif inactivates A3s through proteasomal degradation by recruiting them 
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to E3 ubiquitin ligase complexes (Hultquist et al., 2011; Refsland 
et al., 2012, 2014; Ooms et al., 2013; Aydin et al., 2014; Desimmie 
et  al., 2014; Feng et  al., 2014; Salter et  al., 2014; Okada and 
Iwatani, 2016). Proper counteraction of Vif against A3s is 
necessary for optimal HIV-1 replication.
HIV-1 Vif is highly divergent in patients’ samples. Several 
natural variations in Vif negatively affect its anti-A3 activity 
(Simon et  al., 2005; De Maio et  al., 2011; Ooms et  al., 2013; 
Peng et  al., 2013; Refsland et  al., 2014). Vifs derived from 
different HIV-1 subtypes also counteract A3s in a varying 
degree. Even among isolates from the same subtype, the ability 
of Vif to overcome A3 restriction has been shown to be different 
(Iwabu et  al., 2010; Binka et  al., 2012; Lisovsky et  al., 2013). 
Difference in Vif amino acid sequence can thus alter anti-A3 
activity, thereby influencing HIV-1 replication ability and the 
hypermutation rate of viral genome introduced by A3 deaminase.
HIV-1 generates ~50 mRNAs species coding the nine viral 
proteins through alternative splicing using splicing donors (SD1–
SD4) and splicing acceptors (SA1–SA7) (Purcell and Martin, 1993; 
Amendt et al., 1995). HIV-1 mRNA production is highly regulated 
process, and vif mRNA is generated by utilizing SD1 and SA1. 
Several splicing regulatory elements (SREs) in the HIV-1 genome 
and numerous host proteins are involved in the process (Caputi, 
2011; Karn and Stoltzfus, 2012; Sertznig et al., 2018). We previously 
demonstrated that vif mRNA/Vif protein expression levels are 
altered by naturally occurring single nucleotide variations (nSNVs), 
found within the region around SA1/SD2 through investigation 
of the HIV-1 sequence compendium1. The region was then named 
as SA1D2prox (Figure 1A). We also observed the inverse correlation 
between levels of vif/vpr mRNAs and the Vif/A3G-dependent 
virus growth fluctuation (Widera et  al., 2014; Nomaguchi et  al., 
2016). Moreover, we  found that the RNA stem-loop structure 
formed in the region containing SA1 (Watts et  al., 2009; Pollom 
et  al., 2013) can contribute to determination of vif mRNA 
production level (Nomaguchi et  al., 2017). On the one hand, 
sequence of vif-coding region also contains SA2/SD3 involved 
in vpr mRNA creation, and various SREs close to SA2/SD3 sites 
have been reported (Figure 1B; Karn and Stoltzfus, 2012; Sertznig 
et  al., 2018). Considering the mutually related vif/vpr levels and 
the presence of important elements for splicing, we  hypothesized 
that the levels of vif/vpr and thus, those of Vif/Vpr, may 
be  changeable by sequence variations of the vif-coding region.
In this work, to confirm and extend our previous findings 
described above, we  examined the sequences of SA1D2prox 
and vif from HIV-1 subtypes B and C. It has been reported 
that the subtype C virus shows a higher anti-A3G activity 
than the subtype B, and that the amino acids responsible for 
the difference were determined (Iwabu et  al., 2010). To link 
this finding to our previous results, we  generated chimeric 
viruses between the two subtypes that exhibit distinct anti-A3G 
activity. Here, we  have summarized the results obtained for 
the chimeric viruses, and proposed that viral nucleotide sequence 
of the vif-coding region is also important for vif/Vif expression, 
in addition to the SA1D2prox regulatory sequence.
1 https://www.hiv.lanl.gov
COMPARISON OF NUCLEOTIDE/AMINO 
ACID SEQUENCES AROUND THE VIF 
GENES OF NL4-3 (HIV-1 SUBTYPE B) 
AND INDIE (HIV-1 SUBTYPE C)  
VIRUS CLONES
Based on analysis of the HIV-1 sequence compendium1, we have 
shown that nSNVs found within SA1D2prox (142 nucleotide-
length region from Pol-Integrase R224cgg to just before vif 
start codon) can alter Vif expression level/growth potential 
of HIV-1NL4-3 (Figure 1A; Nomaguchi et  al., 2014, 2016). 
We  were interested in the difference in nucleotide sequence 
that may affect vif/vpr expression levels of subtypes B (NL4-3 
clone) and C (Indie clone) viruses. First, SA1D2prox sequence 
of Indie clone from HIV-1 subtype C was compared to that 
of NL4-3 clone from subtype B. Nucleotide sequences of this 
region between two clones were different (89% sequence 
identity), and several variations that increase or decrease vif 
production level were present in SA1D2prox region in the 
Indie genome (Figure 1A). Second, we  compared vif-coding 
sequence between the two clones. This region contains SA2 
and SD3  in addition to various splicing enhancer (ESEvpr) 
(Figure 1B; Erkelenz et al., 2013) and splicing silencers (ESSV, 
HIVE3D3, and GI3-2) (Figure 1B; Bilodeau et al., 2001; Tsuruno 
et  al., 2011; Widera et  al., 2014). Comparison of the entire 
vif gene between NL4-3 and Indie exhibited 87% sequence 
identity. Nucleotide difference in the vif-coding sequence of 
the two clones was also observed in the region around SA2/
SD3 and in various SREs (Figure 1B).
Various functional and interacting domains in Vif, which are 
required for interaction with A3s and subsequent proteasomal 
degradation, have been identified (Figure 1C; Aydin et  al., 2014; 
Desimmie et al., 2014; Feng et al., 2014; Salter et al., 2014). Identity 
of amino acid sequence between NL4-3 and Indie Vifs is 78%, 
and differences were present in the domains important for anti-A3 
activity. These differences are likely to affect viral anti-A3 activity. 
Of note, the Vif sequence of Indie contains 17 K and 31 V amino 
acid residues that are associated with high anti-A3G activity of 
Vif derived from subtype C (Iwabu et  al., 2010). In total, it is 
quite possible that sequence differences in SA1D2prox and vif 
gene of the subtype B NL4-3 and subtype C Indie may influence 
their anti-A3 activity through different vif/vpr expression levels. 
Previous studies (Widera et  al., 2013; Brillen et  al., 2017; Sertznig 
et  al., 2018) strongly support this prediction.
GENERATION OF PROVIRAL 
RECOMBINANT CLONES WITH 
CHIMERIC SEQUENCES OF  
SA1D2PROX AND VIF GENE
In most studies on antagonism of Vif and A3s reported to 
date (Aydin et  al., 2014; Desimmie et  al., 2014; Feng et  al., 
2014; Salter et  al., 2014), the anti-A3 activity of various Vif 
proteins and/or the restriction activity of various A3s was 
Doi et al. Nucleotide Variations Affect vif/Vif Expression
Frontiers in Microbiology | www.frontiersin.org 3 November 2019 | Volume 10 | Article 2758
evaluated by using expression vectors, not proviral clones. 
However, several elements in the HIV-1 genome, such as 
SA1D2prox (Nomaguchi et  al., 2016), can alter Vif expression 
level. Furthermore, in the alternative splicing of HIV-1 genome 
composed of the sequential multi-event process, long-range 





FIGURE 1 | Sequence alignment and genome organization around the vif gene of HIV-1 proviral clones used in this study. Proviral clones of HIV-1 subtype B (NL4-
3, HIV-1NL4-3; GenBank: AF324493) (Adachi et al., 1986) and subtype C (Indie, HIV-1IndieC1; GenBank: AB023804) (Mochizuki et al., 1999) were used in this study. 
Dots in the nucleotide and amino acid sequences of Indie show the nucleotides and residues identical to those of NL4-3. Sequence identities between regions of 
NL4-3 and Indie are as follows. (1) Nucleotide identity. SA1D2prox, 89%. Vif: nos. 1 to 324 (amino acid no. 108), 87%; no. 325 to 3′end, 87%; nos. 1 to 93 (amino 
acid no. 31), 91%; no. 94 to 3′end, 86%. (2) Amino acid identity for Vif. Nos.1 to 108, 78%; no. 109 to C-terminus, 78%; nos. 1 to 31, 80%; no. 32 to C-terminus, 
78%. (A) Nucleotide sequence alignment of SA1D2prox region. SA1 and SD2 sites are indicated. Based on our previous results (Nomaguchi et al., 2014, 2016), 
single-nucleotide variations within the SA1D2prox in NL4-3 that decrease and increase vif production levels are indicated by green and red letters, respectively, in 
the Indie sequence. Single-nucleotide variations for which their effects on the vif production are not much or have not been determined yet are represented as blue 
and black letters, respectively, in the Indie sequence. Reported SREs, i.e., ESEVif (Exline et al., 2008), ESEM1/M2 (Kammler et al., 2006), G4 motif (Exline et al., 
2008), ESS2b (Brillen et al., 2017), ESE2b (Brillen et al., 2017), and GI2-1 (Widera et al., 2013) are indicated. See also a review (Sertznig et al., 2018). (B) Alignment 
of the vif-coding sequence (positions from 301 to 579). SA2, SD3, and amino acid residue H at position 108 of the Vif protein are indicated. Known splicing 
silencers, ESSV (Madsen and Stoltzfus, 2005), HIVE3D3 (Tsuruno et al., 2011), and GI3-2 (Widera et al., 2014), and a splicing enhancer, ESEvpr (Erkelenz et al., 
2013) are shown as reference. (C) Alignment of Vif amino acid sequence. Red letters indicate residues (17 K and 31 V) reported to be responsible for high anti-A3G 
activity of Vif derived from HIV-1 subtype C (Iwabu et al., 2010). Numbers 31 and 108 marked above sequences show the amino acid positions that were utilized to 
generate chimeric Vif. Domains that are important for proteasomal degradation of A3s are indicated for reference (Feng et al., 2014; Nakashima et al., 2015). (D) 
Genome organization around the vif gene of the HIV-1 proviral clones constructed in this study. SA1D2prox regions derived from NL4-3 and Indie are shown in 
green and orange, respectively. SA1, SD2, SA2, and SD3 are indicated in all clones as shown. Above the chimeric vif gene, the corresponding amino acid residues 
at positions 31/32 and 108/109 of Vif are indicated. Recombinant viral clones between NL4-3 and Indie were generated by amplifying chimeric regions with 
overlapping PCR as indicated at amino acid positions and then by introducing resultant PCR fragments into NL4-3 using unique sites (SbfI in pol and EcoRI in vpr).
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Emery et  al., 2017). Thus, we  investigated, in the context of 
proviral genome, effects of nucleotide sequence variations in 
the SA1D2prox and vif regions on the vif/vpr expression levels 
and on the HIV-1 growth potential. Figure 1D shows recombinant 
viral clones generated in this study as test proviral clones in 
an NL4-3 backbone. We  did not construct chimeric clones 
with a backbone of Indie, because the clone can grow in 
peripheral blood mononuclear cells (Jere et  al., 2004) but not 
in a CXCR4/CCR5-positive cell line MT4/CCR5 (Nomaguchi 
et al., 2013a). Recombinant clones thus generated were classified 
into two groups (Figure 1D): (1) clones that have chimeric 
sequences with respect to the SA1D2prox and vif gene (NLpInV, 
InpNLV, and InpInV) and (2) clones that have chimeric sequences 
at amino acid positions 31 or 108 within Vif (NL/InV1, NL/
InV2, NL/InV3, and NL/InV4).
ALTERATIONS IN THE EXPRESSION 
LEVELS OF VIF/VPR AND VIF/VPR 
OBSERVED FOR CHIMERIC  
PROVIRAL CLONES
We have previously showed that nSNVs within SA1D2prox of 
HIV-1NL4-3 genome can increase or decrease the expression level 
of vif/Vif (Nomaguchi et  al., 2016) and that they concomitantly 
alter the vpr level in an inverse correlation (Widera et  al., 2014; 
Nomaguchi et  al., 2016). Here, we  analyzed effects of sequence 
variations in SA1D2prox and vif on the vif/vpr mRNA production 
by semiquantitative PCR as previously described (Nomaguchi 
et  al., 2016). As shown in Figure 2A, vif production levels of 
NLpInV, InpNLV, and InpInV (the first group of chimeric viruses 
in Figure 1D as described above) were clearly reduced relative 
to that of NL4-3, indicating that vif level is decreased by Indie 
SA1D2prox and vif sequences. In contrast, the second group of 
virus clones carrying chimeric vif (NL/InV1, NL/InV2, NL/InV3, 
and NL/InV4  in Figure 1D) gave different results. While the 
vif level of NL/InV2 and NL/InV4 was comparable to that of 
NL4-3, NL/InV1, and NL/InV3, especially NL/InV1, exhibited a 
considerable reduction in vif level (Figure 2A). This reduction 
may be  due to the Indie nucleotide sequence containing SA2/
SD3 in vif (Figure 1D). Consistent with previous reports (Widera 
et  al., 2014; Nomaguchi et  al., 2016), vpr levels of chimeric 
viral clones were found to inversely correlate with vif levels 
(Figure 2A). Moreover, in good agreement with our data here, 
another study of the HIV-1 splicing based on detailed next-
generation sequencing analyses has revealed that the usage of 
SD1-SA2 (Figure 2A), critical for producing vpr mRNA, clearly 
occupies a higher proportion in the total transcripts of subtype 
C (clone pZM247Fv2) than for subtype B (clone NL4-3) (Emery 
et  al., 2017). InpInV and NL/InV1 with conspicuous decrease 
in vif expression showed remarkable increase in vpr production, 
suggesting that the splice sites involved in vif/vpr mRNA 
production are mutually exclusive as previously described 
(Widera et  al., 2014; Nomaguchi et  al., 2016).
To confirm above results (Figure 2A) by the protein 
expression, we  then performed Western blot analysis of 293T 
cells transfected with chimeric clones and monitored Vif/Vpr 
expression levels. As shown in Figure 2B, the anti-Vif antibody 
could recognize all Vif proteins examined and gave results 
fairly in parallel with those for vif level. The results obtained 
showed that NLpInV, InpNLV, and NL/InV2 expressed Vif 
at a level comparable to NL4-3, and that InpInV, NL/InV1, 
NL/InV3, and NL/InV4 produced Vif at a lower level relative 
to NL4-3, the former three in particular. Observed Vif level 
for NLpInV and InpNLV was apparently higher than that 
expected from the vif expression level (Figure 2A). This could 
be  due to the assay systems used in this study. The 
semiquantitative PCR analysis may be  more sensitive than 
the Western blot analysis to detect differences between samples. 
As for Vpr expression levels, results obtained appeared to 
be  more variable among viral clones tested than those for 
Vif levels (Figure 2B). Compared with NL4-3, clones producing 
a relatively decreased level of Vif (InpInV, NL/InV1, and NL/
InV3) expressed a relatively high level of Vpr. Vpr level relative 
to that of NL4-3 were increased for NLpInV but slightly for 
InpNLV and NL/InV4. Only NL/InV2 exhibited a lower level 
of Vpr relative to NL4-3. Difference in Vpr level among clones 
tested was more obvious than that noted in vpr level: e.g., 
NLpInV vs. InpNLV, InpInV vs. NL/InV1, and NL4-3 vs. 
NL/InV2 (Figures 2A,B). These results may be  due to the 
high affinity of the anti-Vpr antibody used. Taken all together, 
our results show that the nucleotide sequences of SA1D2prox 
and vif-coding region affect the expression levels of vif/vpr 
and Vif/Vpr in the context of proviral genome. Although 
most of our analyses were done in 293T cells, it has been 
demonstrated that the HIV-1 splicing pattern is essentially 
the same in infected lymphocytic CEMx174 cells and in 
transfected 293T cells (Emery et  al., 2017).
A3G-DEGRADING ACTIVITY OF 
CHIMERIC VIRUS CLONES INPINV,  
NL/INV1, AND NL/INV3
Most conspicuous observation in Figure 2B was that clones 
InpInV, NL/InV1, and NL/InV3 express Vif remarkably more 
poorly than the others. We  thus asked how these virus clones 
with such a low Vif expression level are functionally active 
against A3G. To monitor the A3G-degrading activity, 293T 
cells were co-transfected with virus clones and a flag-tagged 
A3G expression vector, and the A3G level within cells was 
determined by Western immunoblot assays as previously 
described (Yamashita et  al., 2008, 2010). Expression levels of 
Vif and Gag-precursor were also determined to confirm the 
validity of the experiment. As shown in Figure 2C, compared 
with positive (NL4-3 and Indie) and negative (NL-∆Vif) controls, 
the three clones were found to degrade A3G to various degrees. 
While clearly low relative to NL4-3 and Indie, InpInV and 
NL/InV1 exhibited distinct A3G-degrading activity. NL/InV1 
expressed a slightly lower level of Vif relative to InpInV, but 
showed slightly higher A3G-degrading activity. Finally, compared 
with NL-∆Vif, even NL/InV3 with the lowest ability displayed 
the A3G-degrading activity at an appreciable level.
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FIGURE 2 | Virological characteristics of NL4-3 and chimeric viral clones newly constructed. Most experiments here were performed similarly as described previously 
(Nomaguchi et al., 2014, 2016, 2017). (A) Semiquantitative PCR analysis. Indicated proviral clones (2.5 μg) were transfected into 293T cells by Lipofectamine 2000 
(Thermo Fischer Scientific), and cell lysates were made at 18 to 20 h post-transfection. Total RNAs were prepared and subjected to cDNA synthesis with oligo(dT) 
(Continued)
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GROWTH PROPERTIES IN WEAKLY 
A3G-POSITIVE AND HIGHLY A3G-
POSITIVE CELL LINES OF CHIMERIC 
VIRUS CLONES THAT EXPRESS 
VARIOUS LEVELS OF VIF
Changes in the Vif expression level affect HIV-1 growth in 
A3G-expressing cells (Mandal et  al., 2009; Widera et  al., 2013, 
2014; Nomaguchi et  al., 2016). We  therefore analyzed the 
association between the altered Vif expression levels and the 
replication abilities. Viruses prepared from transfected 293T cells 
were inoculated into weakly A3G-positive CEM-SS cells, which 
express A3G below virus-restrictive level and highly A3G-positive 
H9 cells (Nomaguchi et  al., 2016). As shown in Figure 2D, 
NL4-3 and all chimeric viruses grew well in CEM-SS cells, 
demonstrating no fundamental defects in the viruses tested. In 
contrast, various growth phenotypes were observed in H9 cells. 
In the first group of the three chimeric viruses (Figure 1D), 
while InpNLV exhibited similar growth potential to NL4-3, 
NLpInV and InpInV similarly grew more slowly than NL4-3. 
Thus, although the vif/Vif expression levels of InpNLV and 
NLpInV were estimated to be  similar, their growth kinetics 
were different. However, we noted that NLpInV expressed more 
Vpr than InpNLV (Figure 2B). Considering inverse correlation 
between expression of the two proteins, it is conceivable that 
NLpInV may actually express a lower level of Vif relative to 
InpNLV, which could not be  detected by the vif/Vif assays 
(Figures 2A,B). Another important point to be mentioned here 
is that, while the vif/Vif levels of InpInV were reduced relative 
to those of NLpInV (Figures 2A,B), the two clones grew similarly. 
In this regard, we  previously found that the vif expression level 
in a certain range (0.16 to 0.47 relative to NL4-3) is sufficient 
to maintain wild-type growth ability (Nomaguchi et  al., 2016). 
This may explain, at least in part, why the growth kinetics of 
the two clones were similar. In the second group of the four 
virus clones that carry chimeric vif sequences (Figure 1D), 
NL/InV1 and NL/InV3 showed a very attenuated growth 
phenotype in highly A3G-positive H9 cells. However, as compared 
with the low Vif-expressing InpInV, the decrease in replication 
ability of NL/InV1 and NL/InV3 was too drastic. It is conceivable 
that, for chimeric Vifs of NL/InV1 and NL/InV3, the alteration 
of functional structure in addition to their expression levels 
may severely negatively affect their anti-A3G activity. Indeed, 
consistent with the results in Figure 2C, NL/InV3 grew much 
more poorly than InpInV in H9 cells. Regarding NL/InV1, 
however, its inability to grow in H9 cells cannot be  explained 
only by the defective anti-A3G activity. NL/InV1 showed a 
slightly higher A3G-degrading activity than InpInV (Figure 2C). 
Upon careful examination of the growth potentials of various 
chimeric clones, we  noticed that, in CEM-SS cells, NL/InV1 
grew more poorly than InpInV and also NL/InV3 (Figure 2D). 
This result was certainly reproduced in the two independently 
performed infection experiments (Figure 2E), and suggested 
that some activity of NL/InV1, other than the Vif activity, may 
be  weaker than that of the other two chimeric clones. This 
possibility remains to be  experimentally confirmed. Of note, 
nucleotide variations and/or spontaneous mutations in the central 
region of HIV-1 genome can affect the viral replication potential 
in a Vif-independent manner (our unpublished data).
In conclusion, our results here clearly show that nucleotide 
sequences of SA1D2prox and vif influence the Vif expression 
level to a virologically significant extent. While a certain level 
of the expression/function of Vif is a prerequisite for HIV-1 
replication, it is possible that the level for Vpr expression, 
inversely correlated with Vif expression, may influence viral 
replication in some cell type. Vpr has been reported to exert 
its function mainly in the myeloid cell lineage (Fujita et  al., 
2010; Guenzel et  al., 2014; González, 2017; Nodder and 
Gummuluru, 2019).
primer. Vif/vpr mRNAs were amplified simultaneously in one reaction using the cDNA as template and a specific primer pair indicated at the top. The 
reverse primer 5,622-3 was designed for the 100% matched sequence between NL4-3 and Indie. Exon7 (amplified by a primer pair indicated at the top) and gapdh 
were used as a transfection control (total level of HIV-1 mRNAs) and an internal control, respectively. Representative data from three independent experiments are 
presented in the lower left portion of this panel. Vif and vpr mRNA levels relative to those of NL4-3 are presented in the lower right portion of this panel. Expression 
levels of vif and vpr mRNAs in each sample were normalized by those of all HIV-1 mRNAs (exon7) and gapdh. Mean values ± standard errors from three 
independent experiments are shown. (B) Western blotting analysis. 293T cells were transfected with 3.5 μg of proviral clones indicated by Lipofectamine 2000, and 
on day 1 post-transfection, cell lysates were prepared. To detect Vif and Vpr proteins, the polyclonal anti-Vif peptide antibody (Akari et al., 1999) and anti-Vpr 
peptide antibody (#3951, NIH Research and References Reagent Program) were used, respectively. These rabbit polyclonal antibodies were raised against a 
synthetic NL4-3 Vif peptide (amino acids 170-184; amino acid identity between NL4-3 and Indie is 9/15 = 60%) and against a synthetic NL4-3 Vpr peptide (amino 
acids 1-46; amino acid identity between NL4-3 and our chimeric clones NLpInV, InpInV, NL/InV1, and NL/InV3 is 45/46 = 98%). β-actin was used as an internal 
control. Representative data from at least two independent experiments are shown. (C) Comparative analysis of the A3G-degrading activity. Ability of virus clones to 
degrade A3G in cells was assessed by the co-transfection experiment as previously described (Yamashita et al., 2008, 2010). A flag-tagged A3G expression vector 
(0.1 μg) and a proviral clone (2.5 μg) were co-transfected into 293T cells, and the A3G expression level in the cells at 48 h post-transfection was monitored by 
Western blotting analysis as described in (B). For detection of the flag-tagged A3G and control Gag (precursor p55) proteins, anti-Flag (Sigma) and anti-Gag (#3537, 
NIH Research and References Reagent Program) antibodies were used, respectively. As a negative control, NL-Nd (∆Vif) which lacks the Vif expression (Adachi 
et al., 1991) was used. Representative data from two independent experiments are shown. (D) Growth kinetics in CEM-SS and H9 cells. Viruses were prepared 
from 293T cells transfected with indicated proviral clones (2.5–5.0 μg) by Lipofectamine 2000 or calcium-phosphate co-precipitation method, and virus amounts 
were determined by the virion-associated reverse transcriptase (RT) assays (Willey et al., 1988; Nomaguchi et al., 2013b). Equal amounts of viruses (104 RT units) 
were inoculated into a weakly A3G-positive cell line CEM-SS and a highly A3G-expressing cell line H9 (105 cells). Culture supernatants were collected every 3 days, 
and virus replication was monitored by RT assays. All viruses were examined for their growth properties in the same single experiment. Results obtained for chimeric 
clones were separately presented in the upper and lower portions of this panel for clarity, and the same NL4-3 data were shown in both graphs for easy 
comparison. Representative data from at least three independent infection experiments performed using virus samples prepared by separate transfections are 
shown. (E) Growth kinetics in CEM-SS cells. A series of infection experiments were performed as described in the legend to (D), and results from two independent 
experiments for InpInV, NL/InV1, and NL/InV3, other than those shown in (D), are presented at upper and lower panels.
FIGURE 2 | 
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CONCLUDING REMARKS
In this work, we  have summarized and studied the effect of 
SA1D2prox and vif-coding sequences on the Vif expression 
level and virus replication ability. By utilizing sequences of 
both regions from HIV-1 subtypes B (NL4-3) and C (Indie) 
viruses with different anti-A3G activity, we  generated chimeric 
proviral clones with the backbone of NL4-3 (Figure 1). Together 
with our previous reports (Nomaguchi et al., 2014, 2016, 2017), 
our results suggest that viral nucleotide sequences of both 
SA1D2prox and vif coding-region contribute to determining 
Vif expression level and consequently affecting HIV-1 replication 
(Figure 2). Interestingly, when natural Vif variants were expressed 
by a certain expression vector, their expression levels were not 
uniform (Simon et  al., 2005; Ooms et  al., 2013).
Many SREs have been identified around SAs/SDs including 
those within SA1D2prox and vif-coding sequence (Caputi, 2011; 
Karn and Stoltzfus, 2012; Sertznig et  al., 2018). Since mutating 
and evolving activity under the host’s environments are 
characteristic of HIV-1, nucleotide sequences in these elements 
and/or in unknown SREs can often be  changed. It is not 
unreasonable to assume that such natural variations may modify 
splicing regulations, and thus may alter the production of 
HIV-1 mRNAs and subsequent expression of viral proteins. 
Some of HIV-1 proviral clones that were generated by global 
synonymous mutagenesis exhibited replication defects caused 
by splicing perturbations, indicating the importance of the 
nucleotide sequence involved in splicing regulation (Takata 
et  al., 2018). In individuals infected with HIV-1, Vif can alter 
its expression level and/or counteracting activity against A3s 
by naturally occurring mutations/variations. It would 
be  advantageous for HIV-1 survival to maintain a certain level 
of antagonism achieved via the expression level and anti-A3 
activity of Vif. Further analyses of the effect of natural 
non-synonymous and synonymous variations, found widely 
among HIV-1 strains, on the gene expression process including 
the splicing regulation would provide vital insights into the 
association between nucleotide changes and HIV-1 replication.
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